Evoke Pharma (EVOK) has provided an announcement.
Evoke Pharma, Inc. has seen pivotal developments, including the appointment of Mark A. Kowieski as CFO, effective May 22, 2024, and a salary boost for CEO Matthew J. D’Onofrio. Additionally, the company has expanded its 2013 Equity Incentive Award Plan, adding 4 million shares and introducing an “evergreen provision” for annual share increases. Stockholders have also sanctioned a doubling of authorized shares to 100 million and various board proposals, including a potential reverse stock split, reflecting strategic moves to bolster Evoke Pharma’s financial and corporate structure.
For detailed information about EVOK stock, go to TipRanks’ Stock Analysis page.
